Teva launched a generic version of Tarceva tablets

Teva Pharmaceutical Industries announced the launch of a generic version of Tarceva tablets, 100 and 150 mg, in the U.S
Erlotinib Tablets are a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Erlotinib Tablets are also indicated for first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine.
“The launch of generic Tarceva ® tablets marks an important addition to our offering of oncology products,” said Brendan O’Grady, EVP and Head of North America Commercial.